Patents by Inventor Jung-Mao HSU

Jung-Mao HSU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND A KIT FOR PREDICTING THE SUSCEPTIBILITY TO STIMULATOR OF INTERFERON GENES (STING) AGONISTS IN A CANCER PATIENT
    Publication number: 20220364181
    Abstract: A method for predicting susceptibility to stimulator of interferon genes (STING) agonists of a cancer patient is provided, comprising (1) obtaining at least one sample from the cancer patient; (2) detecting an expression level of S-methyl-5?-thioadenosine phosphorylase (MTAP) in the at least one sample by using at least one specific probe; and (3) if MTAP is expressed in the at least one sample, then predicting that the cancer patient has high-susceptibility to STING agonists and providing STING agonists to treat the cancer patient; otherwise providing non-STING agonists for treatment.
    Type: Application
    Filed: May 14, 2022
    Publication date: November 17, 2022
    Applicant: China Medical University
    Inventors: Mien-Chie Hung, Jung-Mao Hsu
  • Detection of arginine methylation of EGFR for prediction of resistance to therapy
    Patent number: 11452775
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: September 27, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Hsin-Wei Liao, Jung-Mao Hsu
  • DETECTION OF ARGININE METHYLATION OF EGFR FOR PREDICTION OF RESISTANCE TO THERAPY
    Publication number: 20200093926
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Application
    Filed: December 4, 2019
    Publication date: March 26, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mien-Chie HUNG, Hsin-Wei LIAO, Jung-Mao HSU
  • Detection of arginine methylation of EGFR for prediction of resistance to therapy
    Patent number: 10537635
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: January 21, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Hsin-Wei Liao, Jung-Mao Hsu
  • DETECTION OF ARGININE METHYLATION OF EGFR FOR PREDICTION OF RESISTANCE TO THERAPY
    Publication number: 20160279240
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Application
    Filed: November 19, 2014
    Publication date: September 29, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mien-Chie HUNG, Hsin-Wei LIAO, Jung-Mao HSU